---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-088950"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:43:13.920668+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences Q2 2024 net income $32.7M; cash $123.6M; HBV program on track for IND in 2024

## Summary
- Net income from continuing ops $32.7M vs loss $11.9M YoY; revenue $49.9M (+$30.1M) from Prevail termination.
- Cash $123.6M; expected runway into H2 2026.
- PBGENE-HBV on track for IND/CTA submission in 2024; PBGENE-PMM targeted for 2025.
- Regained control of three preclinical programs from Prevail (DMD, liver, CNS) for internal/partner development.
- Entered into $22.5M term loan with Banc of California (maturity June 2027).

## SEC filing metadata
- accession: 0000950170-24-088950
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017024088950/0000950170-24-088950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017024088950/dtil-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-088950
- JSON: https://secwatch.observer/filing/0000950170-24-088950.json
- Plain text: https://secwatch.observer/filing/0000950170-24-088950.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.